Analysts Set Certara, Inc. (NASDAQ:CERT) PT at $15.92

Certara, Inc. (NASDAQ:CERT) has been assigned a consensus rating of “Hold” from the eight ratings firms that are presently covering the firm, Marketbeat.com reports. Six analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $15.92.

CERT has been the subject of a number of research analyst reports. Robert W. Baird decreased their target price on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research report on Tuesday, November 5th. Barclays lowered their price objective on shares of Certara from $14.00 to $12.00 and set an “equal weight” rating for the company in a research note on Thursday, November 7th. Finally, UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 target price on the stock in a research report on Friday, September 27th.

Certara Trading Up 1.1 %

NASDAQ CERT opened at $11.33 on Tuesday. The stock has a market cap of $1.82 billion, a PE ratio of -56.65, a PEG ratio of 5.86 and a beta of 1.52. Certara has a 12 month low of $9.41 and a 12 month high of $19.87. The company’s 50-day moving average price is $10.78 and its 200-day moving average price is $12.07. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last issued its earnings results on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.02. The business had revenue of $94.80 million for the quarter, compared to the consensus estimate of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The company’s revenue for the quarter was up 10.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.06 EPS. Equities research analysts forecast that Certara will post 0.28 earnings per share for the current year.

Hedge Funds Weigh In On Certara

Several institutional investors and hedge funds have recently bought and sold shares of CERT. Blue Trust Inc. grew its stake in shares of Certara by 112.3% during the third quarter. Blue Trust Inc. now owns 3,925 shares of the company’s stock worth $46,000 after acquiring an additional 2,076 shares during the last quarter. KBC Group NV raised its stake in shares of Certara by 48.2% during the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after buying an additional 1,584 shares during the last quarter. GAMMA Investing LLC raised its position in Certara by 442.2% during the fourth quarter. GAMMA Investing LLC now owns 8,421 shares of the company’s stock valued at $90,000 after acquiring an additional 6,868 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of Certara in the 2nd quarter valued at $152,000. Finally, Algert Global LLC purchased a new stake in Certara during the second quarter worth $156,000. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.